Financial consulting company Nordicus Partners Corporation has formed a new company, NoviThera Aps, with the objective to research and develop a novel and unique monoclonal antibody (mAb) as a novel innovative therapy for the treatment of psoriasis.
Psoriasis is an immune-medicated inflammatory disease that causes keratinocyte hyperproliferation and inflammation. The typical presentation is well-demarcated erythematous plaques with silvery scale on extensor surfaces, scalp, sacral area, and nails (pitting, onycholysis).
The disorder is typical treated with topical cream, phototherapy and severe cases with interleukin antibodies.
NoviThera is developing a novel monclonal antibody treatment that may cure psoriasis or prevent its occurrence.
The invention was made by Alteral Therapeutics in Denmark and the drug development acquired by NoviThera. Allan Wehnert will become CEO of the new company.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
